Omnicell (NASDAQ:OMCL) Given Sell (D+) Rating at Weiss Ratings

Key Points

• Omnicell's stock has been given a Sell (D+) rating by Weiss Ratings, indicating a negative outlook for investors.
• Analysts have mixed opinions on Omnicell, with four rating it as a Buy, three as Hold, and one as Sell, reflecting varying confidence in the stock's performance.
• Despite the downgrade in ratings, Omnicell's shares increased by 4.0% recently, indicating some investor optimism.

Omnicell (NASDAQ:OMCL - Get Free Report)'s stock had its "sell (d+)" rating restated by Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Several other analysts also recently commented on the stock. Wall Street Zen downgraded shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Wells Fargo & Company upped their price target on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research report on Monday, July 21st. Finally, Piper Sandler dropped their price objective on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Omnicell has a consensus rating of "Hold" and a consensus price target of $46.71.

Omnicell Stock Up 4.0%

Shares of NASDAQ:OMCL opened at $31.45 on Wednesday. The company has a market capitalization of $1.44 billion, a PE ratio of 62.90, a P/E/G ratio of 6.61 and a beta of 0.88. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.74. The firm has a 50 day simple moving average of $31.59 and a 200-day simple moving average of $30.52.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company's revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, equities analysts predict that Omnicell will post 1.09 EPS for the current fiscal year.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 3,880 shares of the company's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $33.25, for a total transaction of $129,010.00. Following the transaction, the executive vice president directly owned 110,653 shares of the company's stock, valued at $3,679,212.25. This represents a 3.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.52% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Omnicell

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Lazard Asset Management LLC grew its stake in shares of Omnicell by 3.8% during the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company's stock worth $50,225,000 after purchasing an additional 62,733 shares during the period. Victory Capital Management Inc. grew its stake in shares of Omnicell by 10.1% during the 1st quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock worth $58,745,000 after purchasing an additional 154,038 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Omnicell by 1.3% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company's stock worth $41,854,000 after purchasing an additional 17,680 shares during the period. Geode Capital Management LLC boosted its position in shares of Omnicell by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company's stock worth $35,163,000 after buying an additional 30,678 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its position in shares of Omnicell by 38.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 653,971 shares of the company's stock worth $19,227,000 after buying an additional 181,394 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.